KPV
200 mcg · Daily
Robert
Founder, F*CK Getting Old — independent researcher, not a medical professional.
Last reviewed · 2 cited sources
Evidence
- Human Studies
- 1
- Animal Studies
- 20
- Clinical Status
- Research
- Confidence
- Low
- Long-Term Safety
- Unknown — almost entirely animal-model evidence, minimal human data
What this score is: a measure of how much research exists and how far along it is (animal-only vs. human trials, research-stage vs. FDA approved) — not how safe, effective, or worth trying a compound is. A low score usually means “early stage” or “understudied,” not “bad.” A high score doesn’t mean “better” for your goals than a lower-scored one.
This is not my personal rating of the compound, not a recommendation, and not medical advice. It’s a general research synthesis for informational purposes only, not a live literature count. See the linked research and talk to a licensed clinician before making decisions based on it.
Mechanism
KPV is the C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH), studied mainly in animal models of inflammatory bowel disease and skin inflammation for anti-inflammatory effects that appear largely independent of the pigmentation effects of full-length melanocortin peptides.
Common Protocols
- 200 mcg subcutaneous daily, or oral capsule forms sold for gut-focused use — human dosing for either route is not established by clinical trials
Side Effects
- Limited systematic human safety data
- Injection site irritation (injectable form)
Interactions
- No formal interaction data exists
Practical Details
- Cost
- $
- Typical Vial Size
- 5 mg
- Storage
- Refrigerate after reconstitution (injectable); oral capsules per product label
Key Studies & Reviews
- Dalmasso G et al. (2008). PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. PMID 18061177.
- Kannengiesser K et al. (2008). Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. PMID 18092346.
Search the Research
KPV FAQ
What is the typical KPV dosage?
Commonly reported protocols: 200 mcg subcutaneous daily, or oral capsule forms sold for gut-focused use — human dosing for either route is not established by clinical trials. Our reference entry uses 200 mcg, Daily. These reflect protocols reported in research and user communities, not a medical recommendation — dosing should be decided with a clinician.
What are the side effects of KPV?
Reported side effects include: Limited systematic human safety data; Injection site irritation (injectable form).
Is KPV FDA approved?
KPV is not FDA approved for human use and is generally sold as a research chemical, so purity and dosing are not regulated.
How much research is there on KPV?
Our evidence profile counts roughly 1 human and 20 animal studies, with low overall confidence. Long-term safety: Unknown — almost entirely animal-model evidence, minimal human data.
Does KPV interact with other drugs or supplements?
No formal interaction data exists.
How do I reconstitute KPV?
A common setup is a 5 mg vial mixed with 2 mL of bacteriostatic water, which puts a 200 mcg dose at about 4 units on a U-100 insulin syringe. Use the reconstitution calculator with your own vial and dose to get exact numbers. Storage: Refrigerate after reconstitution (injectable); oral capsules per product label.
Related compounds
Anti-inflammatory tripeptide fragment of alpha-MSH; oral and injectable forms both used informally